Compare GraniteShares 2x Long NVDA Daily ETF (NVDL) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long NVDA Daily ETF vs TransMedics Group Inc — how do they compare? GraniteShares 2x Long NVDA Daily ETF trades at $36.89 (market cap $3.56B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: GraniteShares 2x Long NVDA Daily ETF is the larger of the two by market cap, and GraniteShares 2x Long NVDA Daily ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long NVDA Daily ETF for 15 Days and TransMedics Group Inc for 24 Days on average.
| NVDL | TMDX | |
|---|---|---|
Market Cap | $3.56B | $2.74B |
Volume | 9,740,643 | 949,331 |
Sector | Leveraged / Inverse | Health |
52-Week High | $43.02 | $150.42 |
52-Week Low | $21.76 | $61.99 |
Typical Hold Time | 15 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDL (GraniteShares 2x Long NVDA Daily ETF) trades at $36.905, down 6.73% on the day, with technical indicators showing a bullish bias from moving averages but neutral oscillators. The ETF provides 2x daily leveraged exposure to NVIDIA, which continues to lead AI innovation and recently beat Q2 2027 earnings estimates. Support levels are clustered around $36-$34, with resistance at $38-$41.
While leveraged exposure to NVIDIA's AI leadership offers significant upside potential, NVDL faces risks from daily reset mechanics that can cause performance drift from long-term NVDA returns. Recent articles highlight both optimism about NVIDIA's technical breakout and concerns about the ETF's tracking efficiency. The bullish technical setup suggests near-term opportunity, but volatility remains elevated.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
